Introduction {#sec1}
============

Pluripotent human embryonic stem cells (hESCs) can differentiate into all somatic cells of the human body and hold tremendous potential for developmental biology, drug screening, and regenerative medicine ([@bib38]). The importance of the core pluripotency transcription factors OCT4, NANOG, and SOX2 in the maintenance and induction of pluripotency has been well documented ([@bib3; @bib37; @bib46]). However, a variety of post-transcriptional processes control and alter the original message after transcription. In addition, protein degradation by proteasomes has been suggested to have a vital role maintaining pluripotency ([@bib4; @bib42]). The role of post-transcriptional regulators and protein networks in the maintenance of pluripotency is still largely unknown, especially in human cells.

L1TD1 is highly and specifically expressed in pluripotent cells ([@bib16; @bib26; @bib28; @bib44]) under the control of OCT4, NANOG, and SOX2 ([@bib3; @bib28; @bib44]). We previously reported that L1TD1 is essential for maintaining the pluripotent state in hESCs ([@bib28]). Like LIN28, which is one of the well-characterized post-translational regulators of pluripotency ([@bib15]), L1TD1 is an RNA-binding protein (RBP). RBPs have a fundamental role in a wide variety of cellular processes, including RNA transcription, splicing, processing, localization, stability, and translation. Moreover, each RBP has unique and specific roles ([@bib13]). Given its highly specific expression and vitality in pluripotent cells, we expect that L1TD1 regulates the maintenance of the pluripotent state.

Transcriptomic studies have provided a large amount of data concerning genes that are specifically expressed in the pluripotent state. However, this information can only be used to predict the behavior of proteins that are important for the maintenance of pluripotency. Combinations of mass spectrometry (MS) and bioinformatics studies have increased our understanding of the proteins and pathways that are active in ESCs ([@bib17; @bib40; @bib41]). Only recently, affinity purifications combined with MS have shed light on the protein-protein interaction networks of individual pluripotency factors and the molecular networks that regulate pluripotency. The interactome for Oct4, Sox2, and Nanog, along with other individual transcription factors, has been reported in mouse ESCs (mESCs) ([@bib7; @bib12; @bib23; @bib31; @bib39; @bib43]). However, the functional protein-protein interactions in hESCs have remained unexplored. Notably, the protein networks that are distinct from transcriptional-control networks in pluripotent cells remain unknown.

To elucidate interacting and functional components involved in the regulation of human pluripotency, we characterized proteins associated with L1TD1. Furthermore, we validated selected interactions in hESCs and human induced pluripotent stem cells (hiPSCs). We show that the pluripotency network of L1TD1 is shared with the OCT4, NANOG, and SOX2 interactomes, and contains uncharacterized protein players that are important for maintenance of pluripotency. Our data significantly expand the current knowledge about the biology of RBPs and provide an important resource of protein interactions in human pluripotent cells.

Results {#sec2}
=======

L1TD1 Interactome {#sec2.1}
-----------------

The biological function of a protein is determined by its structure. L1TD1 consists of a C-terminal coiled coil (CC) domain, an RNA recognition motif (RRM) domain, a C-terminal carboxyl tail domain (CTD) domain, and an N-terminal CTD domain ([Figure 1](#fig1){ref-type="fig"}A). The N-terminal RRM domain is exceptional in that only 30 of its C-terminal amino acids (K216--D248) are typical of RRM domains. This "unique sequence" possibly contains the CC domain and the rest of the RRM domain, but it clearly differs from the sequences found in typical CC and RRM domains. Based on these structural domains, we conclude that L1TD1 is an RBP. However, the middle region of L1TD1 contains an exceptional poly-E repeat region. Interestingly, nucleolin, whose structure has an unusual combination of Poly-E and RRM domains, has been shown to specifically recruit proteins that are important for its unique function, with the help of the acidic poly-E region ([@bib9; @bib11; @bib21]). On the basis of these similarities, we speculated that by determining the proteins that interact with L1TD1, we could identify protein complexes that are important for the maintenance of pluripotency.

To identify the L1TD1 protein network and to exclude secondary partners interacting through RNA, we carried out immunoprecipitation (IP) in the presence of RNase with two specific anti-L1TD1 antibodies ([Figure S1](#app2){ref-type="sec"}) that recognize distinct regions of the L1TD1 protein ([Figure 1](#fig1){ref-type="fig"}A). The availability of highly specific antibodies against L1TD1 enabled IP of the endogenous protein, excluding possible overexpression effects. The strategy used to overexpress tagged fusion protein was unsuccessful, as the overexpressed fusion protein of L1TD1 was rapidly cleaved in living cells (data not shown). Liquid chromatography-tandem MS (LC-MS/MS) analysis of three biological replicates resulted in the detection of 306 proteins putatively belonging to the L1TD1 interactome ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). Immunoglobulin G (IgG) control IPs were used as a negative control. In addition, we carried out a CRAPome analysis ([@bib25]) to identify the specificity of the interactions ([Table S2](#mmc3){ref-type="supplementary-material"}).

In order to identify biological processes through which L1TD1 mediates its function, we analyzed the L1TD1 interactome with several of the currently available Gene Ontology and interaction analysis tools. First, we investigated known interactions within the L1TD1 interactome based on the STRING interaction database ([@bib36]). This revealed highly connected components of proteins involved in RNA-processing biology. In particular, RNA translation (21.6%) and splicing (10%) were identified as key functions ([Figure 1](#fig1){ref-type="fig"}C; [Table S3](#mmc4){ref-type="supplementary-material"}). Among the other notable associated functions were intracellular transport (9.6%), protein folding (5.6%), and the proteosomal ubiquitin-dependent protein catabolic process (3%). Ingenuity Pathway Analysis (IPA) further confirmed that the top three functions of L1TD1-interacting proteins were gene expression, post-transcriptional modification, and protein synthesis ([Figure 1](#fig1){ref-type="fig"}D). Collectively, these results suggest that L1TD1 is involved in multiple steps ranging from RNA production to the production of a functional protein.

To establish the validity of the detected interaction network, we confirmed randomly selected individual interactions with specific antibodies ([Figure 1](#fig1){ref-type="fig"}E). In addition, silencing of L1TD1 resulted in reduced expression of most of the interacting partners ([Figure 1](#fig1){ref-type="fig"}F). Taken together with the previous observation that the silencing of L1TD1 has a rapid effect on pluripotency ([@bib28]), our results suggest that interacting proteins that respond to L1TD1 silencing participate in the maintenance of pluripotency along with L1TD1.

L1TD1 Interacts with Multiple RBPs {#sec2.2}
----------------------------------

To gain further insight into the network revealed by these measurements, we classified the L1TD1 interactome on the basis of the structural domains of the interaction partners ([Table S4](#mmc5){ref-type="supplementary-material"}). Based on this, 58 proteins (19%) were classified as ribosomal proteins, providing further evidence that L1TD1 is involved in translation. Interestingly, another major class (10%, 31 proteins) identified was proteins with the RNA-binding domain RRM or KH (K homology), suggesting that L1TD1 performs its function in a complex with other RBPs.

Recently, [@bib19] reported an RNA-binding repertoire of mESCs including 283 RBPs. A comparison of these RBPs with the L1TD1 interactome resulted in the identification of 89 shared RBPs, 72 of which had high significance based on the CRAPome ([Figure 2](#fig2){ref-type="fig"}A). Based on this comparison, 29% of the L1TD1-interacting proteins bind RNA. Moreover, two RBPs that interact with L1TD1, U2af1, and Srsf3 ([Figure 2](#fig2){ref-type="fig"}B) were recently shown to be vital for somatic cell reprogramming in mESCs ([@bib30]).

L1TD1 Traffics between the Nucleus and Cytoplasm {#sec2.3}
------------------------------------------------

Most of the L1TD1-interacting proteins identified were annotated as cytoplasmic in location ([Figure 2](#fig2){ref-type="fig"}C), although more than 30% were nuclear proteins. The presence of nuclear proteins in the L1TD1 interactome led us to reanalyze the cellular location of L1TD1. In a previous study, we localized L1TD1 in the cytoplasmic processing bodies (P-bodies) based on its co-location with AGO2 and LIN28 ([@bib28]). However, both of these proteins are able to traffic between the cytoplasm and nucleus ([@bib2; @bib32]). In addition, a recent MS analysis identified L1TD1 in the nuclear fraction ([@bib33]). To test whether L1TD1 is found in the nucleus, we carried out cell fractionation experiments. The results showed the presence of L1TD1 and LIN28 in both the nuclear and cytoplasmic fractions, whereas OCT4, NANOG, and SOX2 showed extensive nuclear expression ([Figure 2](#fig2){ref-type="fig"}D). The location was also validated in cancer cell lines expressing endogenous L1TD1 ([Figure 2](#fig2){ref-type="fig"}D).

Based on the immunostainings, we concluded that most of the L1TD1 complexes localize adjacent to the nuclear membrane ([Figure 2](#fig2){ref-type="fig"}E). This led us to analyze the L1TD1 interactome for the presence of possible binding partners associated with the nuclear membrane and nuclear pore traffic. In addition to identifying multiple proteins involved in cellular transport, we identified key factors in nuclear pore traffic, such as KPNA2, RAN, and RAE1. Interestingly, karyopherin KPNA2 is enriched in undifferentiated ESCs ([@bib40]) and has been shown to be responsible for the nuclear import of OCT4 ([@bib45]). Furthermore, RAE1 is a component of the nuclear pore complex involved in RNA export ([@bib27]). We validated the cytoplasmic and nuclear location of KPNA2 ([Figure 2](#fig2){ref-type="fig"}D), as well as interactions of KPNA2 and RAE1 with L1TD1 ([Figure 2](#fig2){ref-type="fig"}F). Further, by reciprocal pull-down of KPNA2, we were able to validate the interaction with L1TD1 and OCT4 ([Figure 2](#fig2){ref-type="fig"}F). In addition, we demonstrated that silencing of L1TD1 results in decreased KPNA2 and OCT4 levels ([Figure 2](#fig2){ref-type="fig"}G). These findings strongly suggest that L1TD1 is able to traffic between the nucleus and cytoplasm and participate in nuclear pore traffic.

L1TD1 Levels Are Rapidly Decreased by Proteasome Inhibitor {#sec2.4}
----------------------------------------------------------

The LC-MS/MS analysis resulted in the identification of multiple members of the ubiquitin-dependent proteasome, such as PSMD1, PSMD2, PSMD7, PSMD8, PSMD11, and PSMD14. Of particular interest, PSMD11 was recently reported to be responsible for the increased proteasome activity in hESCs, which is important for the maintenance of pluripotency ([@bib42]). The interaction between L1TD1 and PSMD11 was validated with immunoblotting ([Figure 3](#fig3){ref-type="fig"}A). Moreover, silencing of L1TD1 resulted in decreased levels of PSMD11 ([Figure 3](#fig3){ref-type="fig"}B).

To further study the role of L1TD1 in the proteasome complex, we inhibited proteasome activity with MG-132, which is known to decrease the expression of *SOX2* ([@bib42]). Treatment with MG-132 resulted in an immediate reduction of L1TD1 and SOX2, but did not influence the levels of OCT4 or LIN28 at the early time points studied ([Figure 3](#fig3){ref-type="fig"}C). These results indicate that the protein levels of L1TD1 correlate with proteasome activity and that reduction of L1TD1 expression is an immediate indicator of a decrease in hESC proteasome activity and pluripotency.

L1TD1 Is a Member of the Pluripotency Network {#sec2.5}
---------------------------------------------

To understand the role of L1TD1 in regulating pluripotency, we compared the L1TD1 interactome with lists of proteins ([@bib17; @bib40]) and genes ([@bib1]) that are enriched in hESCs compared with their differentiated counterparts. Based on this analysis, 30% of the L1TD1 interaction partners are associated with pluripotency ([Figures 4](#fig4){ref-type="fig"}A and [S2](#app2){ref-type="sec"}A). Nineteen of the interacting proteins had previously been shown to be enriched in hESCs at both the gene and protein levels. Interestingly, the panel contains several factors, such as DPPA4 (developmental pluripotency associated 4), RFC5 (replication factor C subunit 5), and TOP2A (topoisomerase-IIα), whose role in the regulation of pluripotency remains to be investigated. The interaction of L1TD1 with TOP2A was validated ([Figure S2](#app2){ref-type="sec"}B). In addition, silencing of L1TD1 led to decreased TOP2A levels ([Figure 1](#fig1){ref-type="fig"}F).

L1TD1 belongs to the interactomes of Nanog ([@bib29]) and Oct4 ([@bib7; @bib39]) in mESCs. However, NANOG and OCT4 were not detected as L1TD1-interacting proteins in our MS data. It has proved to be challenging to detect these pluripotency factors with MS ([@bib7; @bib23; @bib31; @bib39]). Therefore, we tested the presence of these proteins by immunoblotting of the L1TD1 IPs. This approach led to the detection of OCT4, NANOG, and SOX2 as L1TD1-interacting proteins ([Figure 4](#fig4){ref-type="fig"}B). Successful optimization of SOX2-IP further verified L1TD1 interaction with SOX2 ([Figure S2](#app2){ref-type="sec"}C). In addition to these transcription factors, we demonstrated that L1TD1 interacts with the pluripotency-related proteins DNMT3B and TRIM28 ([Figure S2](#app2){ref-type="sec"}D). These interactions were initially identified only in individual MS replicates. In addition, silencing of L1TD1 led to decreased TRIM28 levels ([Figure 1](#fig1){ref-type="fig"}F).

Finally, we sought to determine which components of the L1TD1 interactome were also present in the mESC interactomes of OCT4, NANOG, and SOX2 ([Figure 4](#fig4){ref-type="fig"}C) ([@bib7; @bib29; @bib39]). We applied IPA and identified 45, 25, and 8 proteins that interact with OCT4, NANOG, and SOX2, respectively. We then analyzed the gene expression of these factors in human undifferentiated, early differentiated (SSEA3−), and differentiated (embryoid bodies \[EBs\], fibroblasts, and keratinocytes) cells ([Figure 4](#fig4){ref-type="fig"}D). This analysis resulted in the identification of proteins that form the key core of pluripotency at the protein level. In addition to NANOG, L1TD1, LIN28A, SOX2, and OCT4, this analysis suggested that MCM5 (minichromosome maintenance complex component 5), PARP1 (poly ADP-ribose polymerase 1), CDK1 (cyclin-dependent kinase 1), RFC4, and TOP2A could have important roles in the regulation of pluripotency. To evaluate the importance of these factors in terms of pluripotency, we selected one of them to determine the influence of its silencing. Depletion of RFC4 led to an immediate reduction of OCT4 and L1TD1 levels ([Figure 4](#fig4){ref-type="fig"}E), demonstrating that this factor is required for the maintenance of pluripotency.

To confirm our results, we repeated selected L1TD1 protein interactions in hiPSCs ([Figure S2](#app2){ref-type="sec"}E) and tested the specificity of the L1TD1-bead-antibody complex by performing IP in differentiated HeLa control cells compared with pluripotent cells, including the RFC4 interaction ([Figure S2](#app2){ref-type="sec"}F).

Discussion {#sec3}
==========

RBPs are engaged in every aspect of RNA biology and are essential for carrying specific RNA products from the translation machinery to pre-mRNA splicing, transport, localization, translation, and turnover ([@bib13]). Our study indicates that L1TD1 is a functional RBP in human pluripotent cells that is associated with proteins that participate in cellular RNA processes, thus shedding light on the RNA regulation of pluripotent cells.

Several observations support the idea that L1TD1 shuttles between the nucleus and cytoplasm. Based on our results and consistent with a previous report on the subcellular proteome of hESCs ([@bib33]), we conclude that L1TD1 (like LIN28) can be found in cytoplasmic, nuclear, and membrane fractions. Based on the NetNES 1.1 server, the amino acids L811--L814 could be responsible for the nuclear location of L1TD1. As RBPs are known to participate in RNA traffic through nuclear pores, it is possible that L1TD1 has a role in that process. The interaction of L1TD1 with OCT4, SOX2, NANOG, and the nuclear pore traffic protein karyopherin KPNA2 suggests the intriguing possibility that L1TD1 is responsible for the nuclear import of these transcription factors after their translation to protein in the cytoplasm. Highly stem-cell-specific L1TD1 could be responsible for the nuclear localization, thereby controlling these transcription factors and providing an additional checkpoint for the maintenance of pluripotency.

The network shared among L1TD1, OCT4, SOX2, and NANOG is highly interesting. Our analysis suggests that the nuclear epigenetic regulator PARP1 and CDK1 are key proteins in the core pluripotency network. Recently, PARP1 expression and PARylation activity were shown to be increased in undifferentiated mESCs and to regulate nuclear reprogramming ([@bib5; @bib8; @bib20]). In addition, CDK1 was shown to affect the differentiation of mESCs through an interplay with Oct4 ([@bib22]). Our results also revealed a panel of proteins that were not previously reported in the context of self-renewal but may be involved in the regulation of pluripotency. Although the role of TOP2A, RCF4, and MCM5 in pluripotency remains uncharacterized, their contribution to this network and function in other cell types suggest they may have a role in regulation of the cell cycle and DNA replication in pluripotent cells. We chose to further investigate the role of RFC4 and demonstrated that it is vital for maintaining pluripotency.

Post-transcriptional regulators and protein turnover determine which factors are active in pluripotency. Recently, the deubiquitinating enzyme Psmd14 was shown to be essential for cellular reprogramming ([@bib4]), and PSMD11 was shown to regulate increased proteasome activity in hESCs ([@bib42]). However, it is still unclear how proteins are selected for ubiquitination in pluripotent cells. The presence of multiple proteasome subunits in the highly pluripotent-specific L1TD1 interactome suggests that L1TD1 could participate in this selection.

One of the central functional categories detected in the L1TD1 interactome was splicing ([Figure 1](#fig1){ref-type="fig"}C). Cell-type-specific RBPs are able to regulate tissue-specific splicing ([@bib24]), which has been shown to be unique in mESCs and reorganized during reprogramming by RBPs U2af1 and Srsf3 ([@bib30]). The interaction between L1TD1 (identified here in hESCs) and these two factors implies that U2AF1 and SRSF3 also have an important role in human pluripotency, and L1TD1 may play a role in stem-cell-specific splicing.

In addition to regulating pluripotency, L1TD1 may have an important function in cancer. We previously showed that L1TD1 is expressed in selected cancer types, such as colorectal carcinoma, ovarian germ cell tumors, and testis seminomas and non-seminomas ([@bib28]). Interestingly, the L1TD1 interactome reveals many proteins that have an important role or diagnostic value in cancer. For example, KPNA2 has been shown to affect malignant transformation and its elevated expression is correlated with poor diagnosis in multiple forms of cancer ([@bib6]).

Of all the factors in the interactome, L1TD1 has the fastest kinetics in response to differentiation. This implies that L1TD1 has a regulatory role in the maintenance of pluripotency. Moreover, interaction with transcriptional, cell cycle, epigenetic, proteosomal, protein traffic, and splicing regulators further supports the regulatory role of L1TD1. The protein interactome constructed here can be used as an important resource for elucidating individual protein interactions in pluripotent stem cells and possibly in cancer stem cells. Moreover, this analysis sheds light on post-translational regulation in pluripotency and the importance of RBPs in pluripotent cells.

Experimental Procedures {#sec4}
=======================

All experiments were performed in feeder-free culture conditions on Matrigel (BD Biosciences) in mTeSR1 media (Stem Cell Technologies).

For IP, cells were lysed into NP-40 buffer. Lysates were preincubated with 10 μg/ml RNase A (QIAGEN) at +4°C. IP was carried out using M-280 sheep anti-rabbit IgG Dynabeads (11203D; Invitrogen) with L1TD1 HPA030064 (Ab1), HPA028501 (Ab2) (Sigma), SOX-2 \#5024 (Cell Signaling), and normal rabbit IgG 12-370 (Millipore).

IP proteins were gel separated, digested, and submitted for LC-MS/MS analysis. The criteria used for inclusion as an L1TD1-interacting protein were (1) the presence of the protein in two out of three replicates, (2) more than one unique peptide was identified in the L1TD1 IP analysis, and (3) on/off or ≥3-fold enrichment of the identified peptides compared with the control IgG IP reaction.

Detailed methods are described in the [Supplemental Experimental Procedures](#app2){ref-type="sec"}.
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![L1TD1-Interacting Proteins Are Involved in RNA Processing\
(A) Schematic diagram of the human L1TD1 protein structure: coiled coil (CC) domain, RNA recognition motif (RRM) domain, and carboxyl tail domain (CTD). Regions targeted by antibodies 1 and 2 used in the IPs are shown. Protein domain borders are based on [@bib18].\
(B) Venn diagram of the proteins identified in the L1TD1 interactome (shaded area) based on MS analysis of three biological replicates.\
(C) Clusters of the most enriched biological processes in the L1TD1 interactome. Data from the STRING interaction database ([@bib36]) were visualized using Cytoscape 2.8.1 ([@bib34]).\
(D) The three most significant functions of L1TD1 interactome proteins based on Ingenuity Pathway Analysis (IPA). Proteins validated experimentally are shown in red.\
(E) Western blot (WB) validations of individual protein-protein interactions in L1TD1, IgG control, and unbound (UB) IP reactions. NC, negative control. hESC line HS360. CTNNB1 separate IP reaction, DDX3X and PABPC1 separate IP reaction, hESC line H9.\
(F) Protein expression of the interacting proteins after L1TD1 silencing. NT, non-targeting. hESC line HS360. Quantifications can be found in the [Supplemental Results](#app2){ref-type="sec"}.\
See also [Figure S1](#app2){ref-type="sec"} and [Tables S1](#mmc2){ref-type="supplementary-material"}, [S2](#mmc3){ref-type="supplementary-material"}, and [S3](#mmc4){ref-type="supplementary-material"}.](gr1){#fig1}

![The L1TD1 Interactome Uncovers the Importance of RBPs and the Potential Role of L1TD1 in Nuclear Pore Traffic\
(A) RBPs that were both identified here in the L1TD1 interactome in hESCs and previously reported in mESCs ([@bib19]). Proteins were grouped according to the CRAPome percentages (Workflow 1). Proteins with 0.8-1 SAINT probability are shown in bold (Workflow 3).\
(B) WB validation of SRSF3 and U2AF1 interactions in L1TD1, IgG control, and UB IP reactions. hIPSC line HEL 11.4.\
(C) Subcellular location of L1TD1-interacting proteins based on IPA software.\
(D) Expression of L1TD1, KPNA2, LIN28, OCT4, NANOG, SOX2, GAPDH (cytoplasmic control), and PARP1 (nuclear control) in total (T), cytoplasmic (C), and nuclear (N) cell fractions of hESCs (H9), 2102EP embryoteratocarcinoma, and TCAM2 seminoma cell lines.\
(E) Immunostaining of L1TD1 (red), DNA (DAPI staining, blue), NANOG, Phalloidin (actin), and secondary controls in hIPSCs (HEL 11.4).\
(F) WB validation of KPNA2, L1TD1, and RAE1 interactions in L1TD1, KPNA2, IgG control, and UB IP reactions. Additional detections from the experiment shown in [Figure 1](#fig1){ref-type="fig"}E. KPNA2 IP hIPSC line HEL24.3.\
(G) Effect of L1TD1 silencing on the expression of KPNA2 and OCT4. hESC line HS360. Quantifications can be found in the [Supplemental Results](#app2){ref-type="sec"}.\
See also [Table S2](#mmc3){ref-type="supplementary-material"}.](gr2){#fig2}

![L1TD1 Participates in the High Proteasome Activity of Pluripotency\
(A) WB detection of PSMD11 in L1TD1, IgG control, and UB IP reactions. hESC line HS360.\
(B) Protein expression of PSMD11 after L1TD1 silencing. hESC line HS360. NT, non-targeting. Quantifications can be found in the [Supplemental Results](#app2){ref-type="sec"}.\
(C) Protein expression of L1TD1, OCT4, LIN28, SOX2, and GAPDH after inhibition of proteosomal activity with MG-132 inhibitor (10 μM) versus DMSO control. hESC line H9.](gr3){#fig3}

![L1TD1 Connects Uncharacterized Factors to Core Pluripotency Regulation\
(A) hESC-enriched genes ([@bib1]) and proteins ([@bib17; @bib40]) in the L1TD1 interactome. Overlapping hits are listed.\
(B) WB detection of OCT4, SOX2, and NANOG in L1TD1, IgG control, and UB IP reactions. hESC line HS360.\
(C) Proteins that interact with L1TD1 and OCT4 (n = 45), NANOG (n = 25), or SOX2 (n = 8) ([@bib7; @bib29; @bib39]). The figure was constructed with the use of IPA software.\
(D) RNA expression of proteins represented in [Figure 4](#fig4){ref-type="fig"}C in hESCs and differentiated cells. EB, embryoid body; DIFF.K.CYTES, differentiated keratinocytes. Microarray data collected from previous studies ([@bib10; @bib14; @bib35]). The figure was generated from normalized raw files using GeneSpring GX Software (Agilent Technologies Genomics). The top ten differentiation-responsive genes are highlighted in yellow.\
(E) Effect of RFC4 silencing (siRNA1) on the expression of L1TD1 and OCT4. hESC line HS360. Quantifications can be found in the [Supplemental Results](#app2){ref-type="sec"}.\
See also [Figure S2](#app2){ref-type="sec"}.](gr4){#fig4}

[^1]: Co-first author
